Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3

This article has been developed under the scope of the project NORTE-01-0145-FEDER-000013, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER). This work has been funded by European Regional Development Fund funds, through the Competitiveness Factors Operational Programme, and by National funds, through the Foundation for Science and Technology, under the scope of the project POCI-01-0145-FEDER-007038 and through the project POCI-01-0145-FEDER016818 (PTDC/NEU-NMC/3648/2014) and fellowships (SFRH/BD/78388/2011 to S. D-S., SFRH/BD/51059/2010 to A.N.C., SFRH/BPD/91562/2012 to A.S-F., SFRH/BD/51992/2012 to C.S-C, SFRH/BD/88932/2012 to J.M.S.).